Prelim read could come out as early as end of June. Lets hope VX 135 has better performance than PS7977 with a clean profile to advance the program ASAP.
very "unusal activity" in the end. JB just sold 80 k according to filing on 05/06. Bankers know even before insiders whenever big pharma makes an offer. Money always need prior arrangement before any move could be made. VRTX is a big burger and pharma must be drooling. VX 787, VX509, CF and VX 135 with Daclatasvir, what else one need? I hope to see a buyout like VRUS, $69 ABOVE CLOSING PRICE!
CC had unusual number of questions for VX 135. I think Daclatasvir combo result will be watched closely for VRTX. GILD has gained 38 B for its combo pill and VRTX has gained almost none. 2 year behind is nothing in pharm industry.
GILD never ran Phase II A or phase II B of 7977 and GS 5885 combo ( not that I know of) and went to Phase III to document safety after 200 patient data was available. Why VRTX can't do it? What are the risk that BMY will not let any company to run Phase III of Daclatasvir- Combo trial in future?
Xeljanz Euorpean rejection is creating another opportunity to VRTX 509.
VX 809/VX 770 has taken almost 2 months just to start.
Ivacaftor 300,000 x 30,000= 9 B/ year
VX 809/ VX 661 (say discounted) 50000 x 30,000 = 1.5 B/ year
VX 509 ( Xeljanz= PFE) 25000 x (1/10 of estimated 2 Million RA) 200000 = 5 B/ year. Other indications for free.
VX 135 = estimated 1 B/ year
VX 222 = For free ( 80% SVR 4 for GT1 in II A study all oral and 93% SVR 4 in quad therapy)
Telaprevir= 250 Million/ year (going forward)
VX787= For free ( Noval drug with 93% cure rate in Phase II A study)
VRTX has total 218 Million shares
Comments are Welcome
Lets hope VX222 and VX509 can lift this one beyond analysts imaginations
RIGL/AZN RA drug didn't deliver. VX 509 II B results should be out in EULAR this summer.
I am also waiting for VX 222 all oral SVR 24 in G-T 1 a and hoping to see 70% or better results.
VX 135 combo with Daclastavir is an exciting news due to a proven track record of Daclastavir. It is beyond me that market has given 30 B to GILD for PS 7977 and GS 5885 but no one mentions VX 135 potential. I guess we need II B results or 250 patient data for efficacy and safety.